News

Themis publishes compelling Phase 2 results for lead vaccine candidate against Chikungunya fever in "The Lancet"

Details

The recently completed Phase 2 clinical trial was designed to assess the safety, tolerability and immunogenicity of its lead vaccine candidate (MV-CHIK) to protect against Chikungunya fever, a mosquito-transmitted disease that has no current treatment or prevention options. The primary endpoint, defined as the presence of neutralizing antibodies against Chikungunya, four weeks after administration of one or two MV-CHIK injections, was met across all treatment groups. 

Themis announces exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies

Details

Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. 

sphingotec raises €20 million from HBM and Wellington Partners

Details

German diagnostics company sphingotec GmbH has closed a €20m growth equity financing round led by international healthcare specialist investors HBM and Wellington Partners. Sphingotec will primarily use the proceeds to roll out the fully automated IB 10 point-of-care (POC) platform for testing of a broad panel of acute blood biomarkers, which had been acquired in May 2018 through an acquisition of Samsung-subsidiary Nexus Dx Inc. 

  1. Carisma Therapeutics announces $53 million Series A financing
  2. TRiCares closes €22 million Series B financing round
  3. 4SC: Yakult Honsha joins pivotal RESMAIN study of resminostat in CTCL
  4. CEPI partners with Themis to advance vaccines against Lassa fever and MERS
© Wellington Partners, 2019.